Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain

• Published in: Pain (Amsterdam) Vol. 149; no. 1; pp. 33 - 49
• Main Authors: Gao, BaoXi, Hierl, Markus, Clarkin, Kristie, Juan, Todd, Nguyen, Hung, Valk, Marissa van der, Deng, Hong, Guo, Wenhong, Lehto, Sonya G., Matson, David, McDermott, Jeff S., Knop, Johannes, Gaida, Kevin, Cao, Lei, Waldon, Dan, Albrecht, Brian K., Boezio, Alessandro A., Copeland, Katrina W., Harmange, Jean-Christophe, Springer, Stephanie K., Malmberg, Annika B., McDonough, Stefan I.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA Elsevier B.V 01.04.2010; Lippincott Williams & Wilkins, Inc; Elsevier
• Subjects: ABT-594; Analgesics; Analgesics - administration & dosage; Animals; Biological and medical sciences; Chronic Disease; Fundamental and applied biological sciences. Psychology; Humans; Hyperalgesia - diagnosis; Hyperalgesia - drug therapy; Hyperalgesia - physiopathology; Illness and personality; Illness, stress and coping; Ispronicline; Male; Medical sciences; Neuropharmacology; Nicotinic Agonists - administration & dosage; Pain Measurement - drug effects; Pharmacology. Drug treatments; Psychology and medicine; Psychology. Psychoanalysis. Psychiatry; Psychology. Psychophysiology; Rats; Rats, Sprague-Dawley; SSR-180711; SSR-591813; TC-1734; TC-2696; Treatment Outcome; Tropisetron; Varenicline; TC-1734; Varenicline; Ispronicline; SSR-180711; Tropisetron; SSR-591813; TC-2696; ABT-594; Animal model; Spinal cord; Central nervous system; Cytokine; Selectivity; Analgesia; Cholinergic receptor; Analgesic; Pain; Patch; Nicotinic receptor; Subtype; Release
• ISSN: 0304-3959; 1872-6623; 1872-6623
• DOI: 10.1016/j.pain.2010.01.007

Nicotinic acetylcholine receptors (nAChRs) are longstanding targets for a next generation of pain therapeutics, but the nAChR subtypes that govern analgesia remain unknown. We tested a series of nicotinic agonists, including many molecules used or tried clinically, on a panel of cloned neuronal nAChRs for potency and selectivity using patch-clamp electrophysiology and a live cell-based fluorescence assay. Nonselective nicotinic agonists as well as compounds selective either for α4β2 or for α7 nAChRs were then tested in the formalin and complete Freund’s adjuvant models of pain. Nonselective nAChR agonists ABT-594 and varenicline were effective analgesics. By contrast, the selective α4β2 agonist ispronicline and a novel α4β2-selective potentiator did not appear to produce analgesia in either model. α7-selective agonists reduced the pain-related endpoint, but the effect could be ascribed to nonspecific reduction of movement rather than to analgesia. Neither selective nor nonselective α7 nicotinic agonists affected the release of pro-inflammatory cytokines in response to antigen challenge. Electrophysiological recordings from spinal cord slice showed a strong nicotine-induced increase in inhibitory synaptic transmission that was mediated partially by α4β2 and only minimally by α7 subtypes. Taken with previous studies, the results suggest that agonism of α4β2 nAChRs is necessary but not sufficient to produce analgesia, and that the spinal cord is a key site where the molecular action of nAChRs produces analgesia.